ArticleActa neuropathologica communications2014
A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD.
Article in Acta neuropathologica communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- TheMolecular and cellular biology · 2018Article
- Disease Mechanisms ofCold Spring Harbor perspectives in medicine · 2018Review
- Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration.Molecular neurodegeneration · 2017Article
- Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene.Neuroscience letters · 2017Review
- Retraction Note to: A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD.Acta neuropathologica communications · 2016Article
- From animal models to human disease: a genetic approach for personalized medicine in ALS.Acta neuropathologica communications · 2016Review
- C9ORF72-ALS/FTD: Transgenic Mice Make a Come-BAC.Neuron · 2016Article
- Article
- Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.CNS drugs · 2016Review
- C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits.Annals of neurology · 2015Article
- FTD and ALS--translating mouse studies into clinical trials.Nature reviews. Neurology · 2015Review
Corrections and comments
- Retraction · 2016-12-09Error in Analyses · Error in Data · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.